<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11860330</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1635</article-id><article-id pub-id-type="other">EPV1055</article-id><article-id pub-id-type="pii">S0924933824016353</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Esketamine and Hopelessness: Very Short-Term Effects</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rodr&#x000ed;guez Batista</surname><given-names>F. A.</given-names></name><xref rid="aff3531" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1481" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Morales Castellano</surname><given-names>E. E.</given-names></name><xref rid="aff3531" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Morales Rivero</surname><given-names>A. M.</given-names></name><xref rid="aff3531" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez Grimal</surname><given-names>M.</given-names></name><xref rid="aff3531" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Trufero Miguel</surname><given-names>S.</given-names></name><xref rid="aff3532" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff3531"><sup>1</sup>Department of Psychiatry, <institution>Doctor Negr&#x000ed;n University Hospital of Gran Canaria</institution></aff><aff id="aff3532"><sup>2</sup>Department of Psychiatry, <institution>Insular University Hospital of Gran Canaria</institution>, <city>Las Palmas de Gran Canaria</city>. The Canary Islands, <country>Spain</country></aff><author-notes><corresp id="cor1481"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1610">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S785</fpage><lpage>S785</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824016353a.pdf"/><abstract><sec id="sec8902"><title>Introduction</title><p>Treatment Resistant Depression is a challenging condition with a poor outcome and limited therapeutic options. Esketamine is the enantiomer of Ketamine and has recently been approved and marketed for treating depression. Questions remain about its short- and long-term benefit, as well as its usefulness in suicide risk. Hopelessness is one of the symptoms most closely associated with suicide risk.</p></sec><sec id="sec8903"><title>Objectives</title><p>The aim of this paper is to evaluate the effect of this drug on hopelessness after one month of treatment with Esketamine.</p></sec><sec id="sec8904"><title>Methods</title><p>
The Beck Hopelessness Scale (BHS) was administered to patients receiving Esketamine at the Doctor Negr&#x000ed;n University Hospital of Gran Canaria, who provided informed consent and exhibited suicidal ideations and depressive symptoms at the beginning of treatment. This scale was administered before the intranasal administration of Esketamine and after one month of treatment.</p></sec><sec id="sec8905"><title>Results</title><p>Participants (n=5) had an average age of 54,4 years (median 56). We observed variability in the results among the evaluated patients, although the overall trend was a decrease in scores. On average, the patients&#x02019; scores decreased from 14,6 to 7,4 points (with a median change from 14 to 8 points).</p></sec><sec id="sec8906"><title>Conclusions</title><p>Hopelessness improved in the BHS after one month of treatment with Esketamine. These results could be of clinical significance. Hopelessness is associated with suicide risk, so we hypothesize that the improvement could have an impact on it. Nevertheless, we must exercise caution with these results: the sample size is small, patients were taking different medications, and they have diverse medical histories.</p></sec><sec id="sec8907"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>